GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Product-specific reference

Cabotegravir / rilpivirine - CABENUVA intramuscular kit

Read renal action and limits
Local official-label summarySource retrieved 2026-09-10See the evidence for this drug3 sources available - open source summaries, references and comparisons

CABENUVA / cabotegravir rilpivirine / Cabotegravir/rilpivirine

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (2)
Review first - source-specific qualification

Retain the increased-monitoring instruction in severe renal disease

CABENUVA specifies additional adverse-effect monitoring in severe impairment and ESRD. The RX retrieval failed; this addition is official-label content.

Before applying: Confirm HIV-treatment eligibility and injection schedule; do not replace this instruction with APRETUDE wording.

Evidence for this qualification

Source-specific qualification; independent clinician review pending.

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Cabenuva - product and source limitations

Verify the long-acting injectable regimen and the instructions for missed doses.

Before applying: Apply only to the stated formulation, indication and renal population.

Also check: Cabenuva - product and source limitations

Rxlist source

Cabenuva - selected RX renal passage

Choose a product and source Cabenuva | Product label All evidence
Product / population
Cabotegravir/rilpivirine (Cabenuva), long-acting IM injection kit
Renal measure
Use the renal measure explicitly present in the RX passage.
Source revision
Mirror revision not established in the reviewed passage.
Retrieved
2026-11-07 (not the revision date)

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.

This mirror and the underlying product label share a source family.

RX List: selected renal passage

At CrCl 30 to below 90 mL/min no renal adjustment is required for the long-acting injection combination. With severe impairment or ESRD, increase monitoring for adverse effects.

Source revision: Mirror revision not established in the reviewed passage. | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/cabenuva-drug/

Scope: Selected renal passages reviewed; independent clinician adjudication pending. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Added / rechecked in v7.4

Read source findings

Read source-specific summaries and their qualifications. Retrieval date is not label revision date. Recent review does not imply clinical approval.

Official

Cabenuva - labeled renal guidance

Retrieved: 2026-11-07
Source revision: DailyMed SPL version 16, posted Dec 05, 2025

Renal measure: Creatinine clearance (CrCl), mL/min

Read this dated source finding
Rxlist

Cabenuva - selected RX renal passage

Retrieved: 2026-11-07
Source revision: Mirror revision not established in the reviewed passage.

Renal measure: Use the renal measure explicitly present in the RX passage.

Read this dated source finding
See all retained evidence sources
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 2 source difference / applicability notes

Official product label

Cabotegravir / rilpivirine - CABENUVA intramuscular kit

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

CABENUVA intramuscular cabotegravir plus rilpivirine kit for eligible virologically suppressed HIV-1 patients; not PrEP.

Renal method: CrCl, mL/min; source subsection does not name an equation
Retrieved: 2026-09-10

Read local renal resultOpen this source quick answerOpen original reference
Official product label

Cabenuva - labeled renal guidance

Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.

Cabotegravir/rilpivirine (Cabenuva), long-acting IM injection kit

Renal method: Creatinine clearance (CrCl), mL/min
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

Cabenuva - selected RX renal passage

Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.

Cabotegravir/rilpivirine (Cabenuva), long-acting IM injection kit

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Retain the increased-monitoring instruction in severe renal diseaseCabenuva - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 2 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

product and indication

Retain the increased-monitoring instruction in severe renal disease

CABENUVA specifies additional adverse-effect monitoring in severe impairment and ESRD. The RX retrieval failed; this addition is official-label content.

How to use this: Confirm HIV-treatment eligibility and injection schedule; do not replace this instruction with APRETUDE wording.

Cabotegravir / rilpivirine - CABENUVA intramuscular kitCabotegravir - APRETUDE intramuscular injection

Source-specific interpretation; independent clinician adjudication pending.

Source scope / renal recommendation differences

Cabenuva - product and source limitations

Verify the long-acting injectable regimen and the instructions for missed doses.

How to use this: Apply only to the stated formulation, indication and renal population.

Cabenuva - labeled renal guidanceCabenuva - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeCabotegravir / rilpivirine - CABENUVA intramuscular kitCabenuva - labeled renal guidanceCabenuva - selected RX renal passage
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1698baf3-f895-4c42-a1b1-e9ee3f20da36

Exact product and population

CABENUVA intramuscular cabotegravir plus rilpivirine kit for eligible virologically suppressed HIV-1 patients; not PrEP.

RDM57-SCOPE-cabotegravir-rilpivirine-cabenuva · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Cabotegravir / rilpivirine - CABENUVA intramuscular kit

Open original reference

Open / share this exact local source

DailyMed / ViiV Healthcare Company · CABENUVA intramuscular cabotegravir plus rilpivirine kit for eligible virologically suppressed HIV-1 patients; not PrEP.

Renal method: CrCl, mL/min; source subsection does not name an equation
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-10

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

No adjustment is needed at CrCl 30 to below 90 mL/min. At CrCl 15 to below 30 or below 15, the label recommends increased monitoring for adverse effects. ESRD without dialysis has unknown PK; high protein binding makes dialysis unlikely to change exposure.

Use only within the full HIV-treatment eligibility, resistance and injection-schedule requirements. The renal finding differs in scope from APRETUDE monotherapy for prevention. The GlobalRPh CABENUVA mirror failed retrieval in this pass; this locally stored content is from the exact official label, not an imported RX monograph.

RDM57-official-cabotegravir-rilpivirine-cabenuva-5b49d66b05-C1 · Source locator: Sections 1, 8.6 and 12.3

Source-specific limits

Selected sections only; not a complete prescribing monograph or independent clinician approval.

Exact DailyMed HTML identity and named sections checked. Raw SPL XML, original document hash and complete revision history were not obtained.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1698baf3-f895-4c42-a1b1-e9ee3f20da36
Retrieved
2026-09-10
Exact label title
Cabotegravir / rilpivirine - CABENUVA intramuscular kit
DailyMed Set ID
1698baf3-f895-4c42-a1b1-e9ee3f20da36
Labeler
ViiV Healthcare Company
Renal-function method
CrCl, mL/min; source subsection does not name an equation
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
e4284c385c5a56ec366ef6b250230ba34cb9763b374a02b1325f187a89a1b716
Official

Cabenuva - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Cabotegravir/rilpivirine (Cabenuva), long-acting IM injection kit

Renal method: Creatinine clearance (CrCl), mL/min
Source date: DailyMed SPL version 16, posted Dec 05, 2025
Retrieved: 2026-11-07

Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 8.6 Renal Impairment

At CrCl 30 to below 90 mL/min no renal adjustment is required for the long-acting injection combination. With severe impairment or ESRD, increase monitoring for adverse effects. Verify the long-acting injectable regimen and the instructions for missed doses.

RDM74-cabenuva-official-1 · Source locator: Renal guidance: 8.6 Renal Impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1698baf3-f895-4c42-a1b1-e9ee3f20da36
Retrieved
2026-11-07
Renal-function method
Creatinine clearance (CrCl), mL/min
Source date/version
DailyMed SPL version 16, posted Dec 05, 2025
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
3323097dbb8b80e6b0c7f25b2791d9950c4787fb6f66e4ff063f5392a1d354f1
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Cabenuva - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Cabotegravir/rilpivirine (Cabenuva), long-acting IM injection kit

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

At CrCl 30 to below 90 mL/min no renal adjustment is required for the long-acting injection combination. With severe impairment or ESRD, increase monitoring for adverse effects.

RDM74-cabenuva-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/cabenuva-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
d5f983ebd4dfd12936c881fb5d1e769e2d3d87d3d8069fdb137b49d757ff7066

Provenance and preservation

Additional summaries stored on this page: 2 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1698baf3-f895-4c42-a1b1-e9ee3f20da36
Source retrieval
2026-09-10. This is not the source publication or label revision date.
Original source type
source summary
Local text SHA-256
61c98bb983f3703565234b264cafa177b1d201a197509418528d8f27483e4080
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report
Top